Skip to content

US · VKTX · BIOTECHNOLOGY

Viking Therapeutics, Inc. (VKTX) intrinsic value and stock valuation

$24.77as of 2026-11-21 · Mkt cap 3.91B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Viking Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values VKTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VKTX’s statements →

Viking Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 vikingtherapeutics.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-359.64M
20122025
Free cash flow
-$-278.69M
20122025
Total equity
$639.1M+21.2% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-393.34M-$-150.92M-$-100.83M-$-70.36M-$-55.68M
Net income-$-359.64M-$-109.96M-$-85.89M-$-68.87M-$-54.99M
EPSd-$-3.19M-$-1.01M-$-910.33K-$-896.39K-$-712.31K
Operating cash flow-$-278.69M-$-87.79M-$-73.38M-$-48.4M-$-47.59M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-278.69M-$-87.79M-$-73.38M-$-48.4M-$-47.59M
Total assets$715.7M$908.3M$368.5M$168.5M$210.7M
Total debt$140K$1.12M$1.26M$1.56M$30K
Net debt-$-165.67M-$-25.56M-$-54.26M-$-35.07M-$-26.34M
Total equity$639.1M$880.3M$348.4M$145.3M$201.9M
Cash and short-term investments$705.7M$902.6M$362.1M$155.5M$202.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$430K$0.00$0.00$0.00$0.00
Gross profit-$-430K$0.00$0.00$0.00$0.00
Research and development expenses$345M$101.6M$63.8M$54.2M$45M
Selling, general and administrative expenses$48.4M$49.3M$37M$16.1M$10.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$393.3M$150.9M$100.8M$70.4M$55.7M
Cost and expenses$393.3M$150.9M$100.8M$70.4M$55.7M
Interest income$33.7M$40.9M$15M$1.59M$700K
Interest expense$60K$90K$90K$60K$20K
Depreciation and amortization$430K$350K$290K$290K$300K
Ebitda-$-359.15M-$-109.52M-$-85.52M-$-68.52M-$-54.68M
Operating income-$-393.34M-$-150.92M-$-100.83M-$-70.36M-$-55.68M
Total other income/expenses, net$33.7M$41M$14.9M$1.49M$690K
Income before tax-$-359.64M-$-109.96M-$-85.89M-$-68.87M-$-54.99M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-359.64M-$-109.96M-$-85.89M-$-68.87M-$-54.99M
Weighted average shares outstanding$112.7M$109M$94.4M$76.8M$77.2M
Weighted average diluted shares outstanding$112.7M$109M$94.4M$76.8M$77.2M
Balance sheet
20252024202320222021
Cash and short-term investments$705.7M$902.6M$362.1M$155.5M$202.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$715.6M$907.2M$367.2M$167M$210.5M
Property, plant and equipment, net$90K$1M$1.13M$1.42M$30K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$130K$1.1M$1.26M$1.49M$130K
Total assets$715.7M$908.3M$368.5M$168.5M$210.7M
Accounts payable$53.3M$9.81M$7.51M$8.53M$1.44M
Short-term debt$140K$490K$320K$300K$30K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$76.7M$27.4M$19.1M$22M$8.78M
Long-term debt$0.00$630K$940K$1.26M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$630K$940K$1.26M$0.00
Capital lease obligations$140K$1.12M$1.26M$1.56M$30K
Total liabilities$76.7M$28M$20.1M$23.2M$8.78M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-847.55M-$-487.91M-$-377.94M-$-292.05M-$-223.18M
Accumulated other comprehensive income (loss)$380K-$-790K-$-390K-$-1.1M-$-550K
Total equity$639.1M$880.3M$348.4M$145.3M$201.9M
Total investments$539.9M$875.9M$306.6M$118.9M$175.7M
Total debt$140K$1.12M$1.26M$1.56M$30K
Net debt-$-165.67M-$-25.56M-$-54.26M-$-35.07M-$-26.34M
Cash flow statement
20252024202320222021
Net income-$-359.64M-$-109.96M-$-85.89M-$-68.87M-$-54.99M
Depreciation and amortization$430K$350K$290K$290K$300K
Stock-based compensation$40.8M$29.7M$16.8M$8.67M$6.1M
Change in working capital$49M$9.36M$3.55M$10.2M-$-2.93M
Accounts receivable$5.08M$1.2M$320K$610K$1.18M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$43.4M$2.3M-$-1.02M$7.08M-$-2.54M
Net cash provided by operating activities-$-278.69M-$-87.79M-$-73.38M-$-48.4M-$-47.59M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$341.4M-$-553.37M-$-179.09M$54.8M$38M
Common stock issued$2.49M$597.1M$269.8M$0.00$7.59M
Common stock repurchased$0.00$0.00$0.00-$-6.79M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$76.4M$612.5M$271.4M$4.16M$6.88M
Net change in cash$139.1M-$-28.84M$18.9M$10.3M-$-2.75M
Cash at end of period$165.8M$26.7M$55.5M$36.6M$26.4M
Operating cash flow-$-278.69M-$-87.79M-$-73.38M-$-48.4M-$-47.59M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-278.69M-$-87.79M-$-73.38M-$-48.4M-$-47.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Viking Therapeutics, Inc.

        Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

        CEO
        Brian Lian
        Employees
        53
        Beta
        0.66

        Explore

        Frequently asked questions

        What is the intrinsic value of Viking Therapeutics, Inc. (VKTX)?

        InvestorsCraft does not currently publish an intrinsic value for VKTX. How the IC value is calculated.

        Is VKTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for VKTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.